Disc Medicine, Inc. (NASDAQ:IRON) Receives Average Rating of “Moderate Buy” from Brokerages

Disc Medicine, Inc. (NASDAQ:IRON) has been assigned a consensus rating of “Moderate Buy” from the twelve research firms that are presently covering the company, Marketbeat.com reports. One investment analyst has rated the stock with a sell recommendation, one has given a hold recommendation and ten have issued a buy recommendation on the company. The average 1-year target price among brokers that have issued ratings on the stock in the last year is $104.80.

A number of equities analysts have issued reports on IRON shares. TD Cowen reaffirmed a “buy” rating on shares of Disc Medicine in a research note on Friday, December 19th. BMO Capital Markets dropped their target price on shares of Disc Medicine from $120.00 to $100.00 and set an “outperform” rating for the company in a research report on Tuesday, February 17th. Wells Fargo & Company increased their price target on Disc Medicine from $78.00 to $79.00 and gave the company an “overweight” rating in a research note on Monday, March 2nd. Truist Financial reduced their price target on Disc Medicine from $114.00 to $83.00 and set a “buy” rating on the stock in a research report on Friday, February 27th. Finally, Wedbush decreased their price objective on Disc Medicine from $110.00 to $88.00 and set an “outperform” rating for the company in a research note on Tuesday, February 17th.

Insider Activity

In other news, insider William Jacob Savage sold 7,378 shares of the business’s stock in a transaction dated Monday, March 2nd. The stock was sold at an average price of $65.88, for a total transaction of $486,062.64. Following the completion of the transaction, the insider directly owned 85,211 shares in the company, valued at approximately $5,613,700.68. The trade was a 7.97% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider Pamela Stephenson sold 5,531 shares of the company’s stock in a transaction dated Tuesday, February 17th. The shares were sold at an average price of $62.86, for a total value of $347,678.66. Following the completion of the sale, the insider directly owned 80,998 shares of the company’s stock, valued at approximately $5,091,534.28. This trade represents a 6.39% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last 90 days, insiders have sold 54,522 shares of company stock valued at $3,579,979. Insiders own 3.64% of the company’s stock.

Institutional Investors Weigh In On Disc Medicine

Large investors have recently bought and sold shares of the company. Arizona State Retirement System raised its holdings in Disc Medicine by 1.8% in the third quarter. Arizona State Retirement System now owns 6,654 shares of the company’s stock worth $440,000 after purchasing an additional 120 shares during the period. China Universal Asset Management Co. Ltd. increased its position in shares of Disc Medicine by 2.0% in the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 7,094 shares of the company’s stock valued at $469,000 after buying an additional 138 shares in the last quarter. Ameritas Investment Partners Inc. increased its position in shares of Disc Medicine by 8.9% in the 2nd quarter. Ameritas Investment Partners Inc. now owns 2,515 shares of the company’s stock valued at $133,000 after buying an additional 206 shares in the last quarter. Police & Firemen s Retirement System of New Jersey raised its stake in Disc Medicine by 3.3% during the 4th quarter. Police & Firemen s Retirement System of New Jersey now owns 6,716 shares of the company’s stock worth $533,000 after buying an additional 215 shares during the period. Finally, Avanza Fonder AB raised its stake in Disc Medicine by 14.1% during the 4th quarter. Avanza Fonder AB now owns 1,903 shares of the company’s stock worth $151,000 after buying an additional 235 shares during the period. Institutional investors own 83.70% of the company’s stock.

Disc Medicine Stock Performance

Disc Medicine stock opened at $60.09 on Monday. The company has a market cap of $2.29 billion, a PE ratio of -10.03 and a beta of 0.87. The company has a current ratio of 21.94, a quick ratio of 21.94 and a debt-to-equity ratio of 0.04. Disc Medicine has a 1 year low of $30.82 and a 1 year high of $99.50. The company’s 50-day moving average is $67.77 and its two-hundred day moving average is $75.81.

Disc Medicine (NASDAQ:IRON) last issued its quarterly earnings results on Thursday, February 26th. The company reported ($1.62) EPS for the quarter, topping the consensus estimate of ($1.69) by $0.07. The business had revenue of ($19.88) million for the quarter, compared to analyst estimates of $0.15 million. Equities analysts anticipate that Disc Medicine will post -4.07 earnings per share for the current year.

About Disc Medicine

Disc Medicine, Inc (NASDAQ: IRON) is a clinical-stage biotechnology company focused on discovering and developing precision medicines that restore normal cellular function in severe genetic and acquired diseases. The company employs a chemistry-driven approach to identify small molecules that selectively modulate RNA-binding proteins or splicing regulatory pathways. By leveraging proprietary screening and medicinal chemistry platforms, Disc Medicine aims to address diseases with high unmet medical needs and limited treatment options.

The company’s pipeline is anchored by lead programs targeting neuromuscular and hematological disorders.